Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.
Andressa S LainoDavid M WoodsMelinda VassalloXiaozhong QianHao TangMegan Wind-RotoloJeffrey WeberPublished in: Journal for immunotherapy of cancer (2020)
IL-6, CRP and the N/L ratio are prognostic factors with higher levels associated with shorter overall survival in patients with metastatic melanoma receiving ICI or chemotherapy in large randomized trials. In a multi-variable analysis of the randomized phase III Checkmate-067 study, IL-6 was a significant prognostic factor for survival.